DiaMedica Therapeutics Inc. (DMAC) Social Stream

Featured Post From StockTwits About DMAC

$DMAC Brilinta is approved and not very effective and made 6X Dmac's Market cap in one bad quarter. Half the patients using kailikang don't finish the demanding treatment, while patients treated with DM199 in trials have asked to continue even after the study ended. Dmac's current market cap is ridiculous. New 52 week lows on positive data and back to back earnings beating expectations. Not selling.